{"title":"A patient-derived bladder cancer organoid and xenograft platform for personalized drug response prediction and salvage therapeutics screening.","authors":"Junlin Lu, Kaiwen Jie, Chu Liu, Jiajian Lai, Peng Xu, Xinxin He, Kanghua Xiao, Yating Chen, Sen Liu, Zehua Chen, Jianhui Zhang, Zegeng Yang, Shizhi Lin, Qiang Zhang, Ming Huang, Liang Cheng, Siting Chen, Jianmei Zhong, Sheng Li, Hong Li, Xu Chen","doi":"10.21147/j.issn.1000-9604.2026.05.11","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.11","url":null,"abstract":"<p><strong>Objective: </strong>Therapeutic resistance remains a major challenge in bladder cancer treatment. The aim of this study was to develop and validate a bladder cancer patient-derived organoid (PDO)-based platform for treatment response prediction and individualized salvage therapy screening.</p><p><strong>Methods: </strong>A total of 101 patients with bladder cancer were enrolled to establish 75 PDO lines. The optimal culture medium was determined by transcriptome analysis. Consistency validation was performed via histopathology, immunohistochemistry, whole-exome sequencing, and transcriptomic profiling. A three-step high-throughput screening pipeline for 288 approved agents was developed to identify salvage therapies for patients who were multidrug-resistant, which was validated in patient-derived xenograft (PDX) models. A suspension coculture system was constructed to evaluate HER2-targeted chimeric antigen receptor T (CAR-T) cell cytotoxicity and activation.</p><p><strong>Results: </strong>FGF4 supplementation significantly enhanced the 3D growth and establishment efficiency of PDOs, yielding a biobank of 75 bladder cancer PDOs. These PDOs faithfully recapitulated the multidimensional features of parental tumors, and showed preliminary concordance with observed clinical treatment responses (cisplatin, gemcitabine, and epirubicin). To address drug resistance, the high-throughput drug screening pipeline maps individualized sensitivity profiles in four cases. In a patient who was multidrug-resistant, idarubicin was pinpointed as a potent candidate agent, with efficacy confirmed in PDX models. To extend the screening platform beyond chemotherapeutics and cover cellular immunotherapies, we verified that the coculture system enabled HER2 expression-dependent CAR-T cytotoxicity evaluation.</p><p><strong>Conclusions: </strong>This integrated bladder cancer PDO platform provides a clinically relevant individualized tool for treatment response prediction and individualized salvage therapy selection, particularly for patients with multidrug-resistant disease. Its application may support tailored therapeutic decision-making across chemotherapy, targeted therapy, and cellular immunotherapy.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"661-678"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jin Chai, Yunyan Sun, Xuewen Lei, Linjun Zhao, Jie Chen, Ni An, Wenhui Zhang, Yue Wang, Lingyan Ping, Yuqin Song, Hui Yu
{"title":"Statistical cure, dynamic survivorship, and landmark-updated risk assessment in T-lymphoblastic lymphoma: A multicenter cohort study with population-based corroboration.","authors":"Jin Chai, Yunyan Sun, Xuewen Lei, Linjun Zhao, Jie Chen, Ni An, Wenhui Zhang, Yue Wang, Lingyan Ping, Yuqin Song, Hui Yu","doi":"10.21147/j.issn.1000-9604.2026.05.06","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.06","url":null,"abstract":"<p><strong>Objective: </strong>Long-term outcomes in T-lymphoblastic lymphoma (T-LBL) remain incompletely characterized by conventional survival estimates. We aimed to estimate statistical cure and describe landmark-updated survivorship in a multicenter T-LBL cohort defined by tissue diagnosis of a T-lineage lymphoblastic neoplasm with a mass-dominant presentation.</p><p><strong>Methods: </strong>We analyzed 220 patients diagnosed during 2003-2026 at four Chinese centers. Four relative-survival cure models using age-, sex-, and calendar year-matched Chinese population life tables were fitted, with cure timing summarized by a 5% uncured-survival threshold. Landmark analyses at 6, 12, and 24 months assessed subsequent overall survival (OS), progression/relapse status, and exploratory landmark-updated scores. Internal assessment used 500 bootstrap resamples; a population-based Surveillance, Epidemiology, and End Results (SEER) cohort corroborated long-term survivorship patterns.</p><p><strong>Results: </strong>Median follow-up was 60.9 months and 5-year OS was 60.7%. Across models, cure fractions ranged from 57.8% to 59.3% and 5% uncured-survival threshold times ranged from 4.82 to 7.27 years. The principal non-mixture log-logistic model estimated a 57.8% cure fraction and a 7.27-year threshold (bootstrap 95% confidence interval, 4.83-11.65). This threshold exceeded the last observed death (6.24 years) and median follow-up (60.9 months) and therefore represented parametric extrapolation. Landmark cohorts included 193, 161, and 121 patients, with 60, 47, and 26 subsequent deaths. After age and diagnosis-year adjustment, pre-landmark progression/relapse remained associated with subsequent mortality (hazard ratios, 3.32, 3.07, and 3.21). Conditional optimism-corrected concordance indices (C-indices) for the exploratory equal-weight score were 0.696, 0.695, and 0.654; ridge weighting showed no consistent advantage. The 6-month split-sample test-set C-index was 0.498, indicating uncertainty in discrimination. SEER qualitatively corroborated a similar long-term survival pattern.</p><p><strong>Conclusions: </strong>The findings support a long-term survival pattern consistent with population-level statistical cure and the prognostic relevance of updated disease status. Exact cure-time estimates remain model dependent, and the exploratory landmark-updated scores require independent validation before clinical use.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"576-589"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minghao Qin, Jia Fu, Mengjie Fang, Tongyu Zhao, Yuanhe Tian, Ling Wu, Jie Tian, Xuebin Xie, Di Dong
{"title":"Beyond visible anatomy: From CT images to digital biomarkers in gastric cancer.","authors":"Minghao Qin, Jia Fu, Mengjie Fang, Tongyu Zhao, Yuanhe Tian, Ling Wu, Jie Tian, Xuebin Xie, Di Dong","doi":"10.21147/j.issn.1000-9604.2026.05.04","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.04","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"567-571"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identifying tumor microenvironment subtypes in pancreatic neuroendocrine tumors using digital spatial profiling.","authors":"Xiongxiong Lu, Xiaomei Tang, Ziyu Chen, Fanlu Li, Yu Jiang, Yihan Dong, Zhihan Zhang, Jiabin Jin, Zhiwei Xu, Xiaxing Deng, Hao Chen, Chenghong Peng, Wei Huang, Da Fu, Jing Xie","doi":"10.21147/j.issn.1000-9604.2026.05.09","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.09","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to systematically investigate the heterogeneity and correlations between variables within the tumor microenvironment (TME) of primary and metastatic pancreatic neuroendocrine tumors (PanNETs) using digital spatial profiling.</p><p><strong>Methods: </strong>Data from 63 PanNET patients were analyzed, and two distinct sample cohorts were selected for in-depth evaluation. Based on the composition and density of infiltrating immune cells and stromal characteristics, three distinct TME subtypes were identified: T1 (deficient, D), T2 (immune-enriched, IE), and T3 (immune- and fibroblast-enriched, IE/F).</p><p><strong>Results: </strong>The three TME subtypes exhibited distinct clinical prognostic significance, with subtype T3 (IE/F) being associated with the lowest overall survival rates, particularly in metastatic disease (MT3). Molecular characterization revealed substantial variations in gene and protein expression profiles among the subtypes. We further developed an eight-gene prognostic model specifically for identifying MT3 (IE/F), which demonstrated enhanced accuracy for predicting patient survival compared to conventional pathological grading systems.</p><p><strong>Conclusions: </strong>These findings provide critical insights into the complexities of TME and offer a potential framework for personalized treatment strategies for PanNET patients.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"624-644"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gang Xiao, Jiaoyang Ning, Su Wen, Liu Chen, Hao Wen, Keqin Zhang, Jie Yang, Qi Wu, Jing Zhang, Guilong Tanzhu, Min Su, Haibin Deng, Rongrong Zhou
{"title":"Molecular subtyping of brain metastasis-related genes in lung adenocarcinoma via scRNA-seq and bulk RNA-seq integration: A focus on TPX2.","authors":"Gang Xiao, Jiaoyang Ning, Su Wen, Liu Chen, Hao Wen, Keqin Zhang, Jie Yang, Qi Wu, Jing Zhang, Guilong Tanzhu, Min Su, Haibin Deng, Rongrong Zhou","doi":"10.21147/j.issn.1000-9604.2026.05.08","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.08","url":null,"abstract":"<p><strong>Objective: </strong>Brain metastasis (BrM) is a common complication of advanced lung cancer with extremely poor prognosis. This study aimed to establish a molecular classification system for stratifying non-small cell lung cancer (NSCLC)-BrM patients and predicting survival, and to identify key BrM-related molecules and elucidate their mechanisms as potential therapeutic targets.</p><p><strong>Methods: </strong>We integrated single-cell and bulk transcriptomic data to construct molecular subtyping models for predicting lung cancer prognosis and immune microenvironment, and to screen key molecules driving BrM. Based on H1299 and PC9-BrM cells, <i>in vitro</i> experiments demonstrated the regulatory role and mechanism of targeting protein for Xklp2 (TPX2) in lung cancer BrM.</p><p><strong>Results: </strong>We identified 20 BrM-associated genes. Consensus clustering based on these genes stratified patients into two subtypes, with patients in Subtype 2 showing significantly worse overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS). Mechanistic analyses revealed marked activation of proliferation-related pathways in Subtype 2. TPX2 was identified as a critical mediator, with significantly elevated expression in BrM lesions compared with primary lung cancer lesions, and TPX2 overexpression correlated with poorer prognosis. Functional assays in H1299 and PC9-BrM cells demonstrated that <i>TPX2</i> knockdown markedly impaired proliferation, clonogenicity, migration, and invasion. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses and Western blotting validation further indicated that TPX2 likely promotes NSCLC-BrM by activating c-MYC and the epithelial-mesenchymal transition (EMT) process.</p><p><strong>Conclusions: </strong>Our study established a molecular classification system that effectively stratifies NSCLC-BrM patients and predicts survival. Moreover, TPX2 promotes NSCLC-BrM through c-MYC/EMT regulation, offering new insights for targeted therapeutic strategies.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"606-623"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"From stimulator of interferon genes (STING) agonism to STING programming: Opportunities for mRNA cancer vaccines.","authors":"Zheqi Zhou, Qiushi Qin, Chuanhui Han","doi":"10.21147/j.issn.1000-9604.2026.05.02","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.02","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"559-562"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advances in systemic therapy for renal cell carcinoma from treatment intensification to individualized treatment selection.","authors":"Xinyuan Wei, Xu Hu, Zhenhua Liu, Hao Zeng","doi":"10.21147/j.issn.1000-9604.2026.05.05","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.05","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"572-575"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xinyu Du, Shibo Wang, Shuang Wang, Wei Wei, Yongzhan Nie
{"title":"Barriers and promising avenues for clinical translation of neoantigen-based cancer vaccines.","authors":"Xinyu Du, Shibo Wang, Shuang Wang, Wei Wei, Yongzhan Nie","doi":"10.21147/j.issn.1000-9604.2026.05.03","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.03","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"563-566"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comprehensive management of immune-related adverse events in the era of cancer immunotherapy: From reactive treatment to risk stratification and therapeutic coordination.","authors":"Hanping Wang, Binhe Tian","doi":"10.21147/j.issn.1000-9604.2026.05.01","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.01","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"555-558"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Songhan Li, Bo Liu, Liu Yang, Chaobin Wang, Wei Du, Shuwei Zhang, Ran Gao, Jingyu Zhang, Huan Li, Yujing Li, Yiting Chen, Miao Liu, Hai Qi, Shu Wang
{"title":"A progenitor-exhausted (Tpex)-like CD8<sup>+</sup> T-cell compartment extends across axillary lymphatic basin beyond sentinel lymph nodes in breast cancer.","authors":"Songhan Li, Bo Liu, Liu Yang, Chaobin Wang, Wei Du, Shuwei Zhang, Ran Gao, Jingyu Zhang, Huan Li, Yujing Li, Yiting Chen, Miao Liu, Hai Qi, Shu Wang","doi":"10.21147/j.issn.1000-9604.2026.05.07","DOIUrl":"10.21147/j.issn.1000-9604.2026.05.07","url":null,"abstract":"<p><strong>Objective: </strong>The immunological consequences of sparing uninvolved axillary lymph nodes (LNs) in breast cancer remain unclear. We asked whether a transcriptomically defined progenitor-exhausted-like (Tpex-like) CD8<sup>+</sup> T-cell compartment is confined to the sentinel node or distributed across the axillary basin.</p><p><strong>Methods: </strong>We integrated single-cell transcriptomics, paired T-cell receptor (TCR) profiling, and complementary flow cytometry across 15 patients (163,600 cells). We characterized Tpex-like CD8 <i><sup>+</sup></i> T cell populations and assessed their distribution, clonal expansion, and TCR clonotype sharing across sentinel and downstream non-sentinel uninvolved lymph nodes. Complementary flow cytometry was performed to evaluate progenitor-associated T-cell phenotypes at the protein level.</p><p><strong>Results: </strong>Uninvolved LNs were enriched for a C00 Tpex-like cluster characterized by relative enrichment of progenitor-associated TCF7 together with partial exhaustion-lineage features, including TOX expression and TCF7-TOX co-detection, but sparse PDCD1 transcript detection. C00 clonotypes were shared with tumor-infiltrating lymphocytes, whereas metastatic involvement was associated with reduced representation of this compartment. C00 abundance and clonotype-associated properties showed no clear positional differences across sentinel and downstream non-sentinel uninvolved nodes. Independently, flow cytometry detected TCF7/PD-1/TOX progenitor-like phenotypes in downstream non-sentinel uninvolved nodes from five patients; these protein-defined populations were not assumed to be identical to C00.</p><p><strong>Conclusions: </strong>Anatomically distinct uninvolved axillary LNs contain a broadly distributed transcriptomically defined C00 Tpex-like compartment, with complementary protein-level evidence for TCF7<sup>+</sup>PD-1<sup>+</sup>TOX<sup>+</sup> progenitor-like phenotypes. These findings provide a biological framework for considering the immune architecture preserved by axillary de-escalation.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"590-605"},"PeriodicalIF":6.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}